Mesenchymal stem cell therapies in brain disease

Lauren S. Sherman; Matthew P. Romagano; Shauna F. Williams; Pranela Rameshwar

doi:10.1016/j.semcdb.2019.03.003

Mesenchymal stem cell therapies in brain disease

Lauren S. Sherman, Matthew P. Romagano, Shauna F. Williams, Pranela Rameshwar

Research output: Contribution to journal › Review article › peer-review

42 Scopus citations

Abstract

As treatments for diseases throughout the body progress, treatment for many brain diseases has been at a standstill due to difficulties in drug delivery. While new drugs are being discovered in vitro, these therapies are often hindered by inefficient tissue distribution and, more commonly, an inability to cross the blood brain barrier. Mesenchymal stem cells are thus being investigated as a delivery tool to directly target therapies to the brain to treat wide array of brain diseases. This review discusses the use of mesenchymal stem cells in hypoxic disease (hypoxic ischemic encephalopathy), an inflammatory neurodegenerative disease (multiple sclerosis), and a malignant condition (glioma).

Original language	English (US)
Pages (from-to)	111-119
Number of pages	9
Journal	Seminars in Cell and Developmental Biology
Volume	95
DOIs	https://doi.org/10.1016/j.semcdb.2019.03.003
State	Published - Nov 2019

All Science Journal Classification (ASJC) codes

Developmental Biology
Cell Biology

Keywords

Blood brain barrier
Cell therapy
Cytokine
Direct reprogramming
Drug delivery
Mesenchymal stem cell

Access to Document

10.1016/j.semcdb.2019.03.003

Cite this

@article{a84788fe8e5d4af19a52e2f81f87fd5f,

title = "Mesenchymal stem cell therapies in brain disease",

abstract = "As treatments for diseases throughout the body progress, treatment for many brain diseases has been at a standstill due to difficulties in drug delivery. While new drugs are being discovered in vitro, these therapies are often hindered by inefficient tissue distribution and, more commonly, an inability to cross the blood brain barrier. Mesenchymal stem cells are thus being investigated as a delivery tool to directly target therapies to the brain to treat wide array of brain diseases. This review discusses the use of mesenchymal stem cells in hypoxic disease (hypoxic ischemic encephalopathy), an inflammatory neurodegenerative disease (multiple sclerosis), and a malignant condition (glioma).",

keywords = "Blood brain barrier, Cell therapy, Cytokine, Direct reprogramming, Drug delivery, Mesenchymal stem cell",

author = "Sherman, {Lauren S.} and Romagano, {Matthew P.} and Williams, {Shauna F.} and Pranela Rameshwar",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",

year = "2019",

month = nov,

doi = "10.1016/j.semcdb.2019.03.003",

language = "English (US)",

volume = "95",

pages = "111--119",

journal = "Seminars in Cell and Developmental Biology",

issn = "1084-9521",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Mesenchymal stem cell therapies in brain disease

AU - Sherman, Lauren S.

AU - Romagano, Matthew P.

AU - Williams, Shauna F.

AU - Rameshwar, Pranela

PY - 2019/11

Y1 - 2019/11

N2 - As treatments for diseases throughout the body progress, treatment for many brain diseases has been at a standstill due to difficulties in drug delivery. While new drugs are being discovered in vitro, these therapies are often hindered by inefficient tissue distribution and, more commonly, an inability to cross the blood brain barrier. Mesenchymal stem cells are thus being investigated as a delivery tool to directly target therapies to the brain to treat wide array of brain diseases. This review discusses the use of mesenchymal stem cells in hypoxic disease (hypoxic ischemic encephalopathy), an inflammatory neurodegenerative disease (multiple sclerosis), and a malignant condition (glioma).

AB - As treatments for diseases throughout the body progress, treatment for many brain diseases has been at a standstill due to difficulties in drug delivery. While new drugs are being discovered in vitro, these therapies are often hindered by inefficient tissue distribution and, more commonly, an inability to cross the blood brain barrier. Mesenchymal stem cells are thus being investigated as a delivery tool to directly target therapies to the brain to treat wide array of brain diseases. This review discusses the use of mesenchymal stem cells in hypoxic disease (hypoxic ischemic encephalopathy), an inflammatory neurodegenerative disease (multiple sclerosis), and a malignant condition (glioma).

KW - Blood brain barrier

KW - Cell therapy

KW - Cytokine

KW - Direct reprogramming

KW - Drug delivery

KW - Mesenchymal stem cell

UR - http://www.scopus.com/inward/record.url?scp=85063675726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063675726&partnerID=8YFLogxK

U2 - 10.1016/j.semcdb.2019.03.003

DO - 10.1016/j.semcdb.2019.03.003

M3 - Review article

C2 - 30922957

AN - SCOPUS:85063675726

SN - 1084-9521

VL - 95

SP - 111

EP - 119

JO - Seminars in Cell and Developmental Biology

JF - Seminars in Cell and Developmental Biology

ER -

Mesenchymal stem cell therapies in brain disease

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this